Background: Piascledine is a potential treatment for osteoarthritis; however, current evidence regarding its efficacy in patients with knee osteoarthritis remains limited. Objective: To evaluate the efficacy of Piascledine in improving symptoms and its impact on blood lipid levels and body mass index in patients with knee osteoarthritis. Methods: A randomized, controlled, single-blind clinical trial. The odd-numbered group was treated with Piascledine at a dose of 300mg/day, while the even-numbered group was treated with glucosamine sulfate at a dose of 1,500mg/day. Outcomes were assessed at 4 weeks and 8 weeks. Results: A total of 200 patients were included in the study, with a mean age of 58.5 ± 11.3 years, of whom 42.0% were male. Obesity (OR=2.83; 95% CI: 1.88-4.26; p
Key words: Knee osteoarthritis, Piascledine, body mass index, blood lipids.
|
